New drug combo aims to shrink tough lung cancers

NCT ID NCT05949606

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two experimental drugs, SI-B001 and SI-B003, given together with or without chemotherapy in 160 people with advanced non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the combination shrinks tumors. Participants must have tried other treatments or have limited options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SI-B001 and SI-B003 (two experimental drugs given by IV infusion, sometimes with chemotherapy)
What this could lead to: If successful, this could offer a new treatment option for people with advanced non-small cell lung cancer that has not responded to other therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drugs may not prove effective or safe enough for wider use. Side effects from the combination are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai Pulmonary Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.